Metformin: A Potential Therapeutic Tool for Rheumatologists

Metformin is an oral antihyperglycemic drug widely used to treat type 2 diabetes, acting via indirect activation of 5′ Adenosine Monophosphate-activated Protein Kinase (AMPK). Actually, evidence has accumulated of an intriguing anti-inflammatory activity, mainly mediated by AMPK through a variety of mechanisms such as the inhibition of cytokine-stimulated Nuclear Factor-κB (NF-κB) and the downregulation of the Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signaling pathways. Moreover, AMPK plays an important role in the modulation of T lymphocytes and other pivotal cells of the innate immune system. The current understanding of these AMPK effects provides a strong rationale for metformin repurposing in the management of autoimmune and inflammatory conditions. Several studies demonstrated metformin’s beneficial effects on both animal and human rheumatologic diseases, especially on rheumatoid arthritis. Unfortunately, even though data are large and remarkable, they almost exclusively come from experimental investigations with only a few from clinical trials. The lack of support from prospective placebo-controlled trials does not allow metformin to enter the therapeutic repertoire of rheumatologists. However, a large proportion of rheumatologic patients can currently benefit from metformin, such as those with concomitant obesity and type 2 diabetes, two conditions strongly associated with rheumatoid arthritis, osteoarthritis, and gout, as well as those with diabetes secondary to steroid therapy.

[1]  J. Singh,et al.  Gout epidemiology and comorbidities. , 2020, Seminars in arthritis and rheumatism.

[2]  J. Muntané,et al.  Mechanisms of action of metformin in type 2 diabetes: Effects on mitochondria and leukocyte-endothelium interactions , 2020, Redox biology.

[3]  H. Min,et al.  Metformin rescues rapamycin-induced mitochondrial dysfunction and attenuates rheumatoid arthritis with metabolic syndrome , 2020, Arthritis Research & Therapy.

[4]  G. Chodick,et al.  Adherence to metformin and the onset of rheumatoid arthritis: a population-based cohort study , 2020, Scandinavian journal of rheumatology.

[5]  R. Liu-Bryan,et al.  Metformin limits osteoarthritis development and progression through activation of AMPK signalling , 2020, Annals of the Rheumatic Diseases.

[6]  R. Terkeltaub,et al.  Exploration of metformin as novel therapy for osteoarthritis: preventing cartilage degeneration and reducing pain behavior , 2020, Arthritis Research & Therapy.

[7]  R. Marfella,et al.  Metformin: an old drug against old age and associated morbidities. , 2020, Diabetes research and clinical practice.

[8]  D. Veale,et al.  Insulin‐Resistant Pathways Are Associated With Disease Activity in Rheumatoid Arthritis and Are Subject to Disease Modification Through Metabolic Reprogramming: A Potential Novel Therapeutic Approach , 2019, Arthritis & rheumatology.

[9]  J. Rochford,et al.  The burden of metabolic syndrome on osteoarthritic joints , 2019, Arthritis Research & Therapy.

[10]  R. Marfella,et al.  Metformin Lactic Acidosis: should we still be afraid? , 2019, Diabetes research and clinical practice.

[11]  Y. Hung,et al.  Combination of COX-2 inhibitor and metformin attenuates rate of admission in patients with rheumatoid arthritis and diabetes in Taiwan , 2019, Medicine.

[12]  Min-jung Park,et al.  Metformin Augments Anti-Inflammatory and Chondroprotective Properties of Mesenchymal Stem Cells in Experimental Osteoarthritis , 2019, The Journal of Immunology.

[13]  Kun Chen,et al.  Metformin inhibits the proliferation of rheumatoid arthritis fibroblast-like synoviocytes through IGF-IR/PI3K/AKT/m-TOR pathway. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[14]  Ji‐Won Kim,et al.  Metformin improves salivary gland inflammation and hypofunction in murine Sjögren’s syndrome , 2019, Arthritis Research & Therapy.

[15]  F. Cicuttini,et al.  Association between metformin use and disease progression in obese people with knee osteoarthritis: data from the Osteoarthritis Initiative—a prospective cohort study , 2019, Arthritis Research & Therapy.

[16]  H. Haybar,et al.  Metformin one in a Million Efficient Medicines for Rheumatoid Arthritis Complications: Inflammation, Osteoblastogenesis, Cardiovascular Disease, Malignancies. , 2019, Current rheumatology reviews.

[17]  T. Merriman,et al.  mTOR inhibition by metformin impacts monosodium urate crystal–induced inflammation and cell death in gout: a prelude to a new add-on therapy? , 2019, Annals of the rheumatic diseases.

[18]  A. Perl,et al.  Blockade of Treg Cell Differentiation and Function by the Interleukin‐21–Mechanistic Target of Rapamycin Axis Via Suppression of Autophagy in Patients With Systemic Lupus Erythematosus , 2018, Arthritis & rheumatology.

[19]  F. Cicuttini,et al.  Is abnormal glucose tolerance or diabetes a risk factor for knee, hip, or hand osteoarthritis? A systematic review. , 2018, Seminars in arthritis and rheumatism.

[20]  Y. Hung,et al.  Combination COX-2 inhibitor and metformin attenuate rate of joint replacement in osteoarthritis with diabetes: A nationwide, retrospective, matched-cohort study in Taiwan , 2018, PloS one.

[21]  Jinmin Zhao,et al.  Effect of metformin on ossification and inflammation of fibroblasts in ankylosing spondylitis: An in vitro study , 2018, Journal of cellular biochemistry.

[22]  Chul-woo Yang,et al.  Metformin ameliorates experimental-obesity-associated autoimmune arthritis by inducing FGF21 expression and brown adipocyte differentiation , 2018, Experimental & Molecular Medicine.

[23]  S. Tas,et al.  Molecular mechanisms underpinning T helper 17 cell heterogeneity and functions in rheumatoid arthritis. , 2017, Journal of autoimmunity.

[24]  M. Bombardieri,et al.  Current views on the pathogenesis of Sjögren's syndrome , 2017, Current opinion in rheumatology.

[25]  D. Sorriento,et al.  Sirolimus induces depletion of intracellular calcium stores and mitochondrial dysfunction in pancreatic beta cells , 2017, Scientific Reports.

[26]  T. Palmer,et al.  Linking energy sensing to suppression of JAK-STAT signalling: A potential route for repurposing AMPK activators? , 2017, Pharmacological research.

[27]  F. Martinon,et al.  Inflammation in gout: mechanisms and therapeutic targets , 2017, Nature Reviews Rheumatology.

[28]  Rong Li,et al.  Metformin improves obesity-associated inflammation by altering macrophages polarization , 2017, Molecular and Cellular Endocrinology.

[29]  P. Shao,et al.  Modulation of the immune response in rheumatoid arthritis with strategically released rapamycin , 2017, Molecular medicine reports.

[30]  M. Pollak The effects of metformin on gut microbiota and the immune system as research frontiers , 2017, Diabetologia.

[31]  G. De Sarro,et al.  Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis , 2017, Medicine.

[32]  D. A. van der Windt,et al.  Does metformin protect against osteoarthritis? An electronic health record cohort study , 2017, Primary Health Care Research & Development.

[33]  L. Joosten,et al.  Uric acid priming in human monocytes is driven by the AKT–PRAS40 autophagy pathway , 2017, Proceedings of the National Academy of Sciences.

[34]  D. Sabatini,et al.  mTOR Signaling in Growth, Metabolism, and Disease , 2017, Cell.

[35]  D. Shi,et al.  AMPK deficiency in chondrocytes accelerated the progression of instability-induced and ageing-associated osteoarthritis in adult mice , 2017, Scientific Reports.

[36]  Chethan Gejjalagere Honnappa,et al.  A concise review on advances in development of small molecule anti-inflammatory therapeutics emphasising AMPK: An emerging target , 2016, International journal of immunopathology and pharmacology.

[37]  U. Kesavan,et al.  A concise review on advances in development of small molecule anti-inflammatory therapeutics emphasising AMPK: An emerging target. , 2016 .

[38]  Qian Wang,et al.  Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis , 2016, Nature Reviews Rheumatology.

[39]  Vaskar Das,et al.  Adenosine Monophosphate-activated Protein Kinase (AMPK) Activators For the Prevention, Treatment and Potential Reversal of Pathological Pain. , 2016, Current drug targets.

[40]  Seunghoon Lee,et al.  Combination therapy with metformin and coenzyme Q10 in murine experimental autoimmune arthritis , 2016, Immunopharmacology and immunotoxicology.

[41]  A. Perl Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases , 2016, Nature Reviews Rheumatology.

[42]  A. Lurati,et al.  The macrophages in rheumatic diseases , 2016, Journal of inflammation research.

[43]  Z. Nemeth,et al.  The AMPK enzyme-complex: from the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders , 2016, Expert opinion on therapeutic targets.

[44]  Mengqi Guo,et al.  Metformin alleviates vascular calcification induced by vitamin D3 plus nicotine in rats via the AMPK pathway. , 2016, Vascular pharmacology.

[45]  B. Viollet,et al.  AMPK Activation by A-769662 Controls IL-6 Expression in Inflammatory Arthritis , 2015, PloS one.

[46]  Y. Saisho Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect. , 2015, Endocrine, metabolic & immune disorders drug targets.

[47]  Jennifer Lee,et al.  Coenzyme Q10 suppresses Th17 cells and osteoclast differentiation and ameliorates experimental autoimmune arthritis mice. , 2015, Immunology letters.

[48]  Yue-ying Gu,et al.  Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof‐of‐Concept Trial of Metformin , 2015, Arthritis & rheumatology.

[49]  F. Berenbaum,et al.  Association between diabetes mellitus and osteoarthritis: systematic literature review and meta-analysis , 2015, RMD Open.

[50]  P. M. van der Kraan,et al.  Obesity and osteoarthritis, more than just wear and tear: pivotal roles for inflamed adipose tissue and dyslipidaemia in obesity-induced osteoarthritis. , 2015, Rheumatology.

[51]  Huimin Yan,et al.  Suppression of experimental arthritis through AMP-activated protein kinase activation and autophagy modulation. , 2015, Journal of rheumatic diseases and treatment.

[52]  B. Croker,et al.  Normalization of CD4+ T cell metabolism reverses lupus , 2015, Science Translational Medicine.

[53]  J. Ehinger,et al.  Metformin induces lactate production in peripheral blood mononuclear cells and platelets through specific mitochondrial complex I inhibition , 2015, Acta physiologica.

[54]  J. Kopec,et al.  Risk of Type 2 Diabetes among Osteoarthritis Patients in a Prospective Longitudinal Study , 2014, International journal of rheumatology.

[55]  Min-jung Park,et al.  Metformin Attenuates Experimental Autoimmune Arthritis through Reciprocal Regulation of Th17/Treg Balance and Osteoclastogenesis , 2014, Mediators of inflammation.

[56]  F. Blanco,et al.  Mitochondrial dysfunction promotes and aggravates the inflammatory response in normal human synoviocytes. , 2014, Rheumatology.

[57]  S. Jick,et al.  Poorly controlled type 2 diabetes mellitus is associated with a decreased risk of incident gout: a population-based case-control study , 2014, Annals of the rheumatic diseases.

[58]  John P. Ray,et al.  Transcription factor STAT3 and type I interferons are corepressive insulators for differentiation of follicular helper and T helper 1 cells. , 2014, Immunity.

[59]  J. Casanova,et al.  Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells , 2013, The Journal of experimental medicine.

[60]  J. A. MacKay,et al.  A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjögren's syndrome. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[61]  H. Aburatani,et al.  Metabolic regulation of osteoclast differentiation and function , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[62]  D. Wendling,et al.  New bone formation in axial spondyloarthritis. , 2013, Joint, bone, spine : revue du rhumatisme.

[63]  R. Terkeltaub,et al.  Linked decreases in liver kinase B1 and AMP-activated protein kinase activity modulate matrix catabolic responses to biomechanical injury in chondrocytes , 2013, Arthritis Research & Therapy.

[64]  Hyoju Yi,et al.  Metformin downregulates Th17 cells differentiation and attenuates murine autoimmune arthritis. , 2013, International immunopharmacology.

[65]  K. Mills,et al.  Autophagy and inflammatory diseases , 2013, Immunology and cell biology.

[66]  L. Carmona,et al.  Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout , 2013, Annals of the rheumatic diseases.

[67]  F. Berenbaum,et al.  Osteoarthritis, inflammation and obesity , 2013, Current opinion in rheumatology.

[68]  L. Vilá,et al.  Association of Hand or Knee Osteoarthritis With Diabetes Mellitus in a Population of Hispanics From Puerto Rico , 2013, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[69]  Masanori Tamaki,et al.  Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance. , 2012, Journal of applied physiology.

[70]  T. Palmer,et al.  Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation , 2012, Expert opinion on investigational drugs.

[71]  J. Casanova,et al.  Functional STAT3 deficiency compromises the generation of human T follicular helper cells. , 2012, Blood.

[72]  Georg Schett,et al.  The pathogenesis of rheumatoid arthritis. , 2011, The New England journal of medicine.

[73]  S. Wesselborg,et al.  Role of AMPK-mTOR-Ulk1/2 in the Regulation of Autophagy: Cross Talk, Shortcuts, and Feedbacks , 2011, Molecular and Cellular Biology.

[74]  Song Xu,et al.  Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats , 2011, Journal of cellular biochemistry.

[75]  R. Terkeltaub,et al.  Chondrocyte AMP-activated protein kinase activity suppresses matrix degradation responses to proinflammatory cytokines interleukin-1β and tumor necrosis factor α. , 2011, Arthritis and rheumatism.

[76]  Jinxiang Han,et al.  Osteogenic differentiation of human ligament fibroblasts induced by conditioned medium of osteoclast-like cells. , 2011, Bioscience trends.

[77]  P. Goodwin,et al.  Understanding the benefit of metformin use in cancer treatment , 2011, BMC medicine.

[78]  Tomoki Ito,et al.  Neutrophils Activate Plasmacytoid Dendritic Cells by Releasing Self-DNA–Peptide Complexes in Systemic Lupus Erythematosus , 2011, Science Translational Medicine.

[79]  J. Connolly,et al.  Netting Neutrophils Are Major Inducers of Type I IFN Production in Pediatric Systemic Lupus Erythematosus , 2011, Science Translational Medicine.

[80]  J. Tschopp,et al.  Autophagy Controls IL-1β Secretion by Targeting Pro-IL-1β for Degradation , 2011, The Journal of Biological Chemistry.

[81]  Georg Schett,et al.  Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis. , 2010, Arthritis and rheumatism.

[82]  Xia Li,et al.  The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis. , 2010, Biochemical and biophysical research communications.

[83]  Jing Hu,et al.  Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats. , 2010, European journal of pharmacology.

[84]  T. Lockwood The lysosome among targets of metformin: new anti-inflammatory uses for an old drug? , 2010, Expert opinion on therapeutic targets.

[85]  G. Tsokos,et al.  IL-17 in Systemic Lupus Erythematosus , 2010, Journal of biomedicine & biotechnology.

[86]  G. Firestein,et al.  Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritis , 2010, Immunological reviews.

[87]  R. Puenpatom,et al.  Increased Prevalence of Metabolic Syndrome in Individuals with Osteoarthritis: An Analysis of NHANES III Data , 2009, Postgraduate medicine.

[88]  P. Miossec,et al.  IL-17 as a future therapeutic target for rheumatoid arthritis , 2009, Nature Reviews Rheumatology.

[89]  P. Worley,et al.  The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. , 2009, Immunity.

[90]  C. Münz Enhancing immunity through autophagy. , 2009, Annual review of immunology.

[91]  Gheorghe Luta,et al.  Lifetime risk of symptomatic knee osteoarthritis. , 2008, Arthritis and rheumatism.

[92]  Michael J.A. Williams,et al.  Postprandial Cytokine Concentrations and Meal Composition in Obese and Lean Women , 2008, Obesity.

[93]  T. Münzel,et al.  Sirolimus-induced vascular dysfunction. Increased mitochondrial and nicotinamide adenosine dinucleotide phosphate oxidase-dependent superoxide production and decreased vascular nitric oxide formation. , 2008, Journal of the American College of Cardiology.

[94]  J. Alcocer-Varela,et al.  Constitutive STAT3 activation in peripheral CD3+ cells from patients with primary Sjögren's syndrome , 2008, Scandinavian journal of rheumatology.

[95]  P. Tak,et al.  Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study , 2007, Annals of the rheumatic diseases.

[96]  D. Hardie,et al.  AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy , 2007, Nature Reviews Molecular Cell Biology.

[97]  Volker Brinkmann,et al.  Beneficial suicide: why neutrophils die to make NETs , 2007, Nature Reviews Microbiology.

[98]  G. Schett Cells of the synovium in rheumatoid arthritis. Osteoclasts , 2007, Arthritis research & therapy.

[99]  B. Joffe,et al.  Insulin resistance and impaired beta cell function in rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[100]  G L Freeman,et al.  High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. , 2001, Arthritis and rheumatism.

[101]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[102]  M. Owen,et al.  Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. , 2000, The Biochemical journal.

[103]  R. Chakrabarti,et al.  Fibrinolytic treatment of rheumatoid arthritis with phenformin plus ethyloestrenol. , 1966, Lancet.

[104]  R. Terkeltaub,et al.  Emerging regulators of the inflammatory process in osteoarthritis , 2015, Nature Reviews Rheumatology.

[105]  L. See,et al.  Gout: an independent risk factor for all-cause and cardiovascular mortality. , 2010, Rheumatology.

[106]  E. Nasonov,et al.  [Effect of metformin on the clinical course of gout and insulin resistance]. , 2009, Klinicheskaia meditsina.

[107]  Claudia Mauri,et al.  Cells of the synovium in rheumatoid arthritis , 2007 .

[108]  E. Nasonov,et al.  [Use of metformin (siofor) in patients with gout and insulin resistance (pilot 6-month results)]. , 2005, Terapevticheskii arkhiv.

[109]  Henrik J Ditzel,et al.  The K/BxN mouse: a model of human inflammatory arthritis. , 2004, Trends in molecular medicine.

[110]  C. Werning [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.